<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02376699</url>
  </required_header>
  <id_info>
    <org_study_id>SGNS40-001</org_study_id>
    <secondary_id>PN 863</secondary_id>
    <nct_id>NCT02376699</nct_id>
  </id_info>
  <brief_title>Safety Study of SEA-CD40 in Cancer Patients</brief_title>
  <official_title>A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seattle Genetics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seattle Genetics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to find out if SEA-CD40 is safe and effective when given alone, in
      combination with pembrolizumab, and in combination with pembrolizumab, gemcitabine, and
      nab-paclitaxel. The study will test increasing doses of SEA-CD40 given at least every 3 weeks
      to small groups of patients. The goal is to find the highest dose of SEA-CD40 that can be
      given to patients that does not cause unacceptable side effects. Different dose regimens will
      be evaluated. Different methods of administration may be evaluated. The pharmacokinetics,
      pharmacodynamic effects, biomarkers of response, and antitumor activity of SEA-CD40 will also
      be evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be conducted in the following parts:

      Part A: Intravenous (IV) monotherapy dose-regimen finding for solid tumors --
      Dose-escalation, and possible dose-interval modification to lengthen the treatment cycle, to
      define the IV SEA-CD40 monotherapy maximum tolerated dose (MTD) and/or the optimal biological
      dose (OBD) regimens in patients with solid tumors. The ability to increase the dose intensity
      (to give additional doses within a treatment cycle) may be evaluated.

      Part B: IV monotherapy solid tumor expansion cohorts -- Disease-specific solid tumor
      expansion cohorts may be enrolled where patients will be treated with doses at or below the
      IV SEA-CD40 monotherapy MTD and/or OBD determined in Part A.

      Part C: IV monotherapy dose-regimen finding for lymphomas -- Dose-escalation, and possible
      dose-interval modification to lengthen the treatment cycle, to define the IV SEA-CD40
      monotherapy MTD and/or the OBD regimens in patients with lymphomas. The ability to increase
      the dose intensity (to give additional doses within a treatment cycle) may be evaluated.

      Part D: IV monotherapy lymphoma expansion cohorts -- Disease-specific lymphoma expansion
      cohorts may be enrolled where patients will be treated with doses at or below the IV SEA-CD40
      monotherapy MTD and/or OBD determined in Part C.

      Part E: Combination therapy dose-regimen finding for solid tumors -- IV SEA-CD40
      dose-escalation to define the MTD and/or the OBD regimen to be administered in combination
      with standard approved dose of pembrolizumab in patients with solid tumors.

      Part F: Combination therapy solid tumor expansion cohorts -- Disease-specific solid tumor
      expansion cohorts may be enrolled where patients will be treated with IV SEA-CD40 and
      pembrolizumab combination therapy; doses of SEA-CD40 will be at or below the MTD and/or OBD
      determined in Part E.

      Part G: Subcutaneous (SC) injection (injected under the skin) monotherapy dose-regimen
      finding for solid tumors -- Dose-escalation, and possible dose-interval modification to
      lengthen the treatment cycle, to define the SC SEA-CD40 monotherapy maximum tolerated dose
      (MTD) and/or the optimal biological dose (OBD) regimens in patients with solid tumors.

      Part H: SC monotherapy solid tumor expansion cohorts -- Disease-specific solid tumor
      expansion cohorts may be enrolled where patients will be treated with doses at or below the
      SC SEA-CD40 monotherapy MTD and/or OBD determined in Part G.

      (Note: There is no Part I)

      Part J: SC monotherapy dose-regimen finding for lymphomas -- Dose-escalation, and possible
      dose-interval modification to lengthen the treatment cycle, to define the SC SEA-CD40
      monotherapy MTD and/or the OBD regimens in patients with lymphomas.

      Part K: SC monotherapy lymphoma expansion cohorts -- Disease-specific lymphoma expansion
      cohorts may be enrolled where patients will be treated with doses at or below the SC SEA-CD40
      monotherapy MTD and/or OBD determined in Part J.

      Part L: Combination therapy in pancreatic cancer -- Patients will be treated with SEA-CD40
      doses at or below MTD and/or OBD. An established dose of pembrolizumab and a standard regimen
      of gemcitabine and nab-paclitaxel will be used.

      In Parts A, C, E, G, and J, a maximum feasible dose (MFD) will be defined if an MTD and/or
      OBD cannot be identified. Parts B, D, F, H, K. and L will explore the recommended dosing
      regimen once the MTD and/or OBD, or MFD (if the MTD and/or OBD cannot be identified) has been
      determined.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2015</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events (Parts A-K)</measure>
    <time_frame>Through 6 weeks following last dose, up to an average of 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of laboratory abnormalities (Parts A-K)</measure>
    <time_frame>Through 6 weeks following last dose, up to an average of 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate (ORR) per RECIST according to investigator assessment in the efficacy-evaluable population (Part L)</measure>
    <time_frame>Through 6 weeks following last dose, up to an average of 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (Part L)</measure>
    <time_frame>Through 6 weeks following last dose, up to an average of 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR per iRECIST (Part L)</measure>
    <time_frame>Through 6 weeks following last dose, up to an average of 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR (Parts A-K)</measure>
    <time_frame>Through 6 weeks following last dose, up to an average of 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (All Parts)</measure>
    <time_frame>Through 6 weeks following last dose, up to an average of 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (All Parts)</measure>
    <time_frame>Up to approximately 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (All Parts)</measure>
    <time_frame>Up to approximately 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (All Parts)</measure>
    <time_frame>Up to approximately 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax (maximum observed concentration)</measure>
    <time_frame>Through 6 weeks following last dose, up to an average of 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax (time of maximum observed concentration)</measure>
    <time_frame>Through 6 weeks following last dose, up to an average of 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast (AUC from time 0 to last quantifiable timepoint)</measure>
    <time_frame>Through 6 weeks following last dose, up to an average of 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf (AUC from time 0 to infinity)</measure>
    <time_frame>Through 6 weeks following last dose, up to an average of 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent total clearance</measure>
    <time_frame>Through 6 weeks following last dose, up to an average of 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2 (apparent terminal elimination half-life)</measure>
    <time_frame>Through 6 weeks following last dose, up to an average of 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of antitherapeutic antibodies against SEA-CD40</measure>
    <time_frame>Through 6 weeks following last dose, up to an average of 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood concentrations of SEA-CD40</measure>
    <time_frame>Through 6 weeks following last dose, up to an average of 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">135</enrollment>
  <condition>Cancer</condition>
  <condition>Carcinoma</condition>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <condition>Carcinoma, Squamous Cell</condition>
  <condition>Hematologic Malignancies</condition>
  <condition>Hodgkin Disease</condition>
  <condition>Lymphoma</condition>
  <condition>Lymphoma, B-Cell</condition>
  <condition>Lymphoma, Follicular</condition>
  <condition>Lymphoma, Large B-Cell, Diffuse</condition>
  <condition>Melanoma</condition>
  <condition>Neoplasms</condition>
  <condition>Neoplasm Metastasis</condition>
  <condition>Neoplasms, Head and Neck</condition>
  <condition>Neoplasms, Squamous Cell</condition>
  <condition>Non-Small Cell Lung Cancer</condition>
  <condition>Non-Small Cell Lung Cancer Metastatic</condition>
  <condition>Non-small Cell Carcinoma</condition>
  <condition>Squamous Cell Cancer</condition>
  <condition>Squamous Cell Carcinoma</condition>
  <condition>Squamous Cell Carcinoma of the Head and Neck</condition>
  <condition>Squamous Cell Neoplasm</condition>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <condition>Pancreatic Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>IV Monotherapy in Solid Tumors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SEA-CD40 administered IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV Monotherapy in Lymphomas</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SEA-CD40 administered IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination Therapy in Solid Tumors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SEA-CD40 (administered IV) + pembrolizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SC Monotherapy in Solid Tumors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SEA-CD40 administered SC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SC Monotherapy in Lymphomas</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SEA-CD40 administered SC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination Therapy in Pancreatic Cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SEA-CD40 (administered IV) + pembrolizumab + gemcitabine + nab-paclitaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous (IV) SEA-CD40</intervention_name>
    <description>Given intravenously; schedule is cohort-specific.</description>
    <arm_group_label>Combination Therapy in Pancreatic Cancer</arm_group_label>
    <arm_group_label>Combination Therapy in Solid Tumors</arm_group_label>
    <arm_group_label>IV Monotherapy in Lymphomas</arm_group_label>
    <arm_group_label>IV Monotherapy in Solid Tumors</arm_group_label>
    <other_name>SEA-CD40</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Given intravenously; schedule is cohort-specific.</description>
    <arm_group_label>Combination Therapy in Pancreatic Cancer</arm_group_label>
    <arm_group_label>Combination Therapy in Solid Tumors</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Subcutaneous (SC) SEA-CD40</intervention_name>
    <description>Given subcutaneously on Day 1 every 3 weeks</description>
    <arm_group_label>SC Monotherapy in Lymphomas</arm_group_label>
    <arm_group_label>SC Monotherapy in Solid Tumors</arm_group_label>
    <other_name>SEA-CD40</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>1000 mg/m^2 given intravenously on Day 1, 8, and 15 of each 28-day cycle</description>
    <arm_group_label>Combination Therapy in Pancreatic Cancer</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel</intervention_name>
    <description>125 mg/m^2 given intravenously on Day 1, 8, and 15 of each 28-day cycle</description>
    <arm_group_label>Combination Therapy in Pancreatic Cancer</arm_group_label>
    <other_name>Abraxane</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  (Monotherapy - Parts A, B, C, D, G, H, J, and K) -- Histologically confirmed advanced
             malignancy, either: (a) Metastatic or unresectable solid malignancy; or (b) Classical
             Hodgkin lymphoma (HL), or diffuse large B-cell lymphoma (DLBCL), or indolent lymphoma
             (including follicular lymphoma [FL])

          -  (Monotherapy - Parts A, B, C, D, G, H, J, and K) -- Relapsed, refractory, or
             progressive disease, specifically: (a) Solid tumors: Following at least 1 prior
             systemic therapy, and no further standard therapy is available for the patient's
             advanced solid tumor at the time of enrollment; or (b) Classical HL: Following at
             least 2 prior systemic therapies in patients who are not candidates for autologous
             stem cell transplant (SCT), or following failure of autologous SCT; or (c) DLBCL:
             Following at least 1 prior systemic therapy; patients must have also received
             intensive salvage therapy unless they refused or were deemed ineligible; or (d)
             Indolent lymphoma: Following at least 1 prior chemoimmunotherapy regimen that included
             an anti-CD20 monoclonal antibody and for which no other more appropriate treatment
             option exists

          -  (Combination Therapy - Part E and Part F) -- Histologically or cytologically confirmed
             advanced or metastatic solid malignancy for which pembrolizumab treatment is approved.
             In Part F, other advanced solid tumor indications may be eligible as identified by the
             Sponsor.

          -  (Pancreatic Cancer Cohort - Part L) - Histologically or cytologically confirmed
             metastatic exocrine ductal adenocarcinoma of the pancreas not amenable to curative
             therapy. Patients must not have received any prior systemic therapy for metastatic
             disease; patients who have received prior therapy for non-metastatic pancreatic
             adenocarcinoma are eligible if therapy was fully completed more than 4 months before
             start of study treatment.

          -  Representative baseline tumor tissue sample is available (Parts A-K)

          -  Measurable disease

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Adequate baseline hematologic, renal, and hepatic function

          -  Recovery to Grade 1 of any clinically significant toxicity attributed to prior
             anticancer therapy prior to initiation of study drug administration

        Exclusion Criteria:

          -  Parts A-K

               1. Prior chemotherapy, small molecule inhibitors, and/or other investigational
                  anticancer agents (excluding investigational monoclonal antibodies) within 4
                  weeks

               2. Prior radiotherapy: therapeutic radiotherapy within 4 weeks, or palliative
                  radiotherapy (to non-CNS disease) within 1 week

               3. Prior immune-checkpoint inhibitors within 4 weeks (or 8 weeks, if immuno-oncology
                  doublet used as the prior line of therapy)

               4. Prior monoclonal antibodies, antibody-drug conjugates, or radioimmunoconjugates
                  within 4 weeks (or 2 weeks if patient experienced disease progression on the
                  prior treatment)

               5. Prior T-cell or other cell-based therapies within 12 weeks (or 2 weeks if patient
                  experienced disease progression on the prior treatment)

          -  Part L

               1. History of radiation pneumonitis

               2. Neuropathy Grade 2 or higher

               3. Has received prior therapy with an anti-PD-1, anti-PDL1, or anti-PD-L2 agent,
                  with an agent directed to another stimulatory or co-inhibitory T-cell receptor

               4. Has had allogenic tissue/solid organ transplant

          -  All Parts

               1. Recent or ongoing serious infections within 2 weeks

               2. Known positivity for hepatitis B infection

               3. Known active hepatitis C infection

               4. Active autoimmune or auto-inflammatory ocular disease within 6 months

               5. Known or suspected active organ-threatening autoimmune disease

               6. Active central nervous system tumor or metastases

          -  Patients with lymphomas: prior allogeneic SCT

          -  Patients in Part E, F, or L: history of severe immune-mediated adverse reactions or
             severe hypersensitivity to pembrolizumab
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Schmitt, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Seattle Genetics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seattle Genetics Trial Information Support</last_name>
    <phone>866-333-7436</phone>
    <email>clinicaltrials@seagen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>HOPE Line Patient Referral</last_name>
      <phone>205-996-4673</phone>
      <email>phase1referral@uab.edu</email>
    </contact>
    <investigator>
      <last_name>Amitkumar Mehta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christiana Ansong</last_name>
      <phone>312-563-4101</phone>
      <email>Christiana_Ansong@rush.edu</email>
    </contact>
    <investigator>
      <last_name>Ashiq Masood, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Belen Martinez-Caro Aguado</last_name>
      <phone>773-834-2895</phone>
      <email>bmartinezcaroa@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Hedy Kindler, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>University of Michigan Cancer Answer Line</last_name>
      <phone>800-865-1125</phone>
    </contact>
    <investigator>
      <last_name>Mark Zalupski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute / Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria LaBush</last_name>
      <phone>313-576-8711</phone>
      <email>labushv@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Elisabeth Heath</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chelsea McCabe</last_name>
      <phone>551-996-4725</phone>
      <email>Chelsea.McCabe@hackensackmeridian.org</email>
    </contact>
    <investigator>
      <last_name>Martin Gutierrez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Cancer Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tegan VandenBosch</last_name>
      <phone>505-272-4946</phone>
      <email>tvandenbosch@nmcca.org</email>
    </contact>
    <investigator>
      <last_name>Emrullah Yilmaz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UNC Lineberger Comprehensive Cancer Center / University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Garbarino</last_name>
      <phone>984-974-8662</phone>
      <email>jennifer_garbarino@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Juneko Grilley-Olson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University / University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cancer Information Services Inbox</last_name>
      <phone>800-641-2422</phone>
    </contact>
    <investigator>
      <last_name>David Bajor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Burt</last_name>
      <phone>503-215-5696</phone>
      <email>Andrea.Burt@providence.org</email>
    </contact>
    <contact_backup>
      <last_name>Mary McCormick</last_name>
      <phone>503-215-5696</phone>
      <email>Mary.McCormick@Providence.org</email>
    </contact_backup>
    <investigator>
      <last_name>Gina Vaccaro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center / University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrien Van Roosbroeck</last_name>
      <phone>713-745-4367</phone>
      <email>KVan1@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Sarina Piha-Paul, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance / University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1023</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SCCA Phase 1 Program</last_name>
      <phone>206-288-7551</phone>
      <email>Phase1@u.washington.edu</email>
    </contact>
    <investigator>
      <last_name>Andrew Coveler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 6, 2020</verification_date>
  <study_first_submitted>February 17, 2015</study_first_submitted>
  <study_first_submitted_qc>February 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2015</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CD40 Antigen</keyword>
  <keyword>Drug Therapy</keyword>
  <keyword>Follicular Lymphoma</keyword>
  <keyword>Hodgkin Disease</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Indolent Lymphoma</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Lymphoma, B-Cell</keyword>
  <keyword>Lymphoma, Large B-Cell, Diffuse</keyword>
  <keyword>Lymphoma, Non-Hodgkin</keyword>
  <keyword>Monoclonal Antibody</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Neoplasm Metastasis</keyword>
  <keyword>Solid tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Neoplasms, Squamous Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

